EPO and congenital myasthenic syndrome: An in vitro preliminary study has suggested that the earliest erythroid progenitors, the burst-forming unit-erythroid (BFU-E), isolated from CMS patients are more sensitive to recombinant human Epo and have prolonged viability compared with those of healthy high-altitude dwellers (1).